Table I.

Treatment with anti-TGF-β and anti-IL-4 mAbs weakens therapeutic potential of Salmonella-CFA/1 induced CD4⁺ T cells. ^a

Treatment b	CIA/Total c	Day Onset d	Max. Score e	Average score f	CS g
PBS	10/10	27.8 ± 1.6	10	7.2 ± 0.78	50.4 ± 7.11
H696CD4+ T cells and IgG	4/10	33 ± 5.35	4	1.44 ± 0.65* †	7.78 ± 4.65* †
H696CD4+ T cells and anti-IL-4	8/8	26.71 ± 2.29	8	3.62 ± 0.96	34.87 ± 11.09
H696CD4+ T cells and anti-TGF-β	8/8	27.25 ± 2.43	12	5.75 ± 0.86	49.37 ± 10.13

^aArthritis was induced in DBA/1 mice with 100 μg bovine CII in complete Freund’s adjuvant on day 0.

^bSalmonella-CFA/1 primed CD4⁺ T cells were adoptively transferred to mice with induced arthritis on day 15. Intra-peritoneal mAb treatments were initiated on day of transfer, then weekly for a total of four doses (1 mg total of mAb/mouse).

^cNumber of mice with CIA /total in a group for 43 days after CII challenge.

^dMean day ± SEM of first symptoms onset in diseased mice only.

^eMaximum score in group in entire observation period.

^fAverage clinical score per group on day 43 post-induction (end of observation period) calculated as sum of individual scores divided by the number of mice in group ± SEM.

^*P < 0.005 as compared to PBS group;

^†P < 0.05 as compared to anti-IL-4 or anti-TGF-β mAb treated group.

^gCumulative scores (CS) calculated as all scores during the period of observation divided by number of mice in each group.

^*P < 0.005 as compared to PBS and anti-TGF-β treated groups;

^†P < 0.05 as compared to anti-IL-4 treated group.